

**OASL Antibody (C-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AW5164**

**Specification**

---

**OASL Antibody (C-term) - Product Information**

Application	<b>WB, IHC-P,E</b>
Primary Accession	<a href="#">Q15646</a>
Reactivity	<b>Human</b>
Host	<b>Rabbit</b>
Clonality	<b>Polyclonal</b>
Calculated MW	<b>H=59,44 KDa</b>
Isotype	<b>Rabbit IgG</b>
Antigen Source	<b>HUMAN</b>

**OASL Antibody (C-term) - Additional Information**

**Gene ID** 8638

**Antigen Region**  
484-514

**Other Names**

OASL; TRIP14; 2'-5'-oligoadenylate synthase-like protein;  
2'-5'-OAS-related protein; 59 kDa 2'-5'-oligoadenylate synthase-like  
protein; Thyroid receptor-interacting protein 14; p59 OASL

**Dilution**

WB~~1:1000  
IHC-P~~1:50~100

**Target/Specificity**

This OASL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 484-514 amino acids from the C-terminal region of human OASL.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

OASL Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**OASL Antibody (C-term) - Protein Information**

**Name** OASL

**Synonyms** TRIP14

**Function**

Does not have 2'-5'-OAS activity, but can bind double- stranded RNA. Displays antiviral activity against encephalomyocarditis virus (EMCV) and hepatitis C virus (HCV) via an alternative antiviral pathway independent of RNase L.

**Cellular Location**

[Isoform p56]: Nucleus, nucleolus. Cytoplasm.

**Tissue Location**


Expressed in most tissues, with the highest levels in primary blood Leukocytes and other hematopoietic system tissues, colon, stomach and to some extent in testis

**OASL Antibody (C-term) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**OASL Antibody (C-term) - Images**



Western blot analysis of lysates from U-87 MG, PC-3, HT-29 cell line (from left to right), using OASL Antibody (T499)(Cat. #AW5164). AW5164 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 20ug per lane.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

#### **OASL Antibody (C-term) - Background**

2-prime,5-prime oligoadenylates (2-5As) bind to and activate RNase L, leading to degradation of RNA and inhibition of protein synthesis. 2-5As are produced by 2-5A synthetases (OASs), a highly-conserved family of interferon-induced enzymes. The predicted 514-amino acid human p59OASL (2-5A synthetases-like) protein shares a highly conserved N-terminal domain with other OASs. The C-terminal portion of p59OASL contains 2 ubiquitin-like domains. p59OASL is expressed in most tissues, with the highest levels in hematopoietic tissues, colon, and stomach.

#### **OASL Antibody (C-term) - References**

- Hovnanian, A., et al., *Genomics* 56(3):362-363 (1999).
- Rebouillat, D., et al., *Eur. J. Biochem.* 257(2):319-330 (1998).
- Hartmann, R., et al., *Nucleic Acids Res.* 26(18):4121-4128 (1998).
- Lee, J.W., et al., *Mol. Endocrinol.* 9(2):243-254 (1995).
- Mackay, V., et al., *J. Biol. Chem.* 251(12):3716-3719 (1976).